Di S - Search Results

1

A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells.

Wu X, Shi B, Zhang J, Shi Z, Di S, Fan M, Gao H, Wang H, Gu J, Jiang H, Li Z. Wu X, et al. Among authors: di s. Mol Ther. 2017 Oct 4;25(10):2270-2279. doi: 10.1016/j.ymthe.2017.06.026. Epub 2017 Jul 3. Mol Ther. 2017. PMID: 28757080 Free PMC article.

2

Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.

Di S, Li Z. Di S, et al. Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11. Sci China Life Sci. 2016. PMID: 26968709 Review.

3

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.

Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z. Yu M, et al. Among authors: di s. Mol Ther. 2018 Feb 7;26(2):366-378. doi: 10.1016/j.ymthe.2017.12.012. Epub 2017 Dec 19. Mol Ther. 2018. PMID: 29339014 Free PMC article.

4

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Pan Z, Di S, Shi B, Jiang H, Shi Z, Liu Y, Wang Y, Luo H, Yu M, Wu X, Li Z. Pan Z, et al. Among authors: di s. Cancer Immunol Immunother. 2018 Oct;67(10):1621-1634. doi: 10.1007/s00262-018-2221-1. Epub 2018 Aug 4. Cancer Immunol Immunother. 2018. PMID: 30078052 Free PMC article.

5

Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.

Wu X, Luo H, Shi B, Di S, Sun R, Su J, Liu Y, Li H, Jiang H, Li Z. Wu X, et al. Among authors: di s. Mol Ther. 2019 Aug 7;27(8):1483-1494. doi: 10.1016/j.ymthe.2019.04.020. Epub 2019 Apr 29. Mol Ther. 2019. PMID: 31078430 Free PMC article.

6

Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.

Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H. Liu Y, et al. Among authors: di s. J Immunol. 2019 Jul 1;203(1):198-207. doi: 10.4049/jimmunol.1800033. Epub 2019 May 29. J Immunol. 2019. PMID: 31142602

7

Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.

Sun R, Luo H, Su J, Di S, Zhou M, Shi B, Sun Y, Du G, Zhang H, Jiang H, Li Z. Sun R, et al. Among authors: di s. Mol Ther. 2021 Jan 6;29(1):60-74. doi: 10.1016/j.ymthe.2020.09.034. Epub 2020 Sep 26. Mol Ther. 2021. PMID: 33010818 Free PMC article.

8

Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.

Zhou M, Chen M, Shi B, Di S, Sun R, Jiang H, Li Z. Zhou M, et al. Among authors: di s. Mol Ther. 2022 Nov 2;30(11):3379-3393. doi: 10.1016/j.ymthe.2022.07.021. Epub 2022 Aug 4. Mol Ther. 2022. PMID: 35927951 Free PMC article.

9

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.

Jiang H, Song B, Wang P, Shi B, Li Q, Fan M, Di S, Yang J, Li Z. Jiang H, et al. Among authors: di s. Protein Cell. 2017 Dec;8(12):926-931. doi: 10.1007/s13238-017-0472-9. Protein Cell. 2017. PMID: 28929447 Free PMC article. No abstract available.

10

Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.

Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H. Chen M, et al. Among authors: di s. Biomed Pharmacother. 2019 May;113:108734. doi: 10.1016/j.biopha.2019.108734. Epub 2019 Mar 5. Biomed Pharmacother. 2019. PMID: 30849636 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters